Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Articles by Butuo Li
Deep Learning-Driven Anticancer Drug Discovery: Emodepside as a Potential Therapeutic Candidate for Triple-Negative Breast Cancer Click to copy article link Article link copied!
1. Introduction Click to copy section linkSection link copied! Breast cancer is the most prevalent malignancy among women worldwide, and triple-negative breast cancer (TNBC) accounts for 15–20% of breast cancers, causing the highest recurrence and mortality rate among all subtypes.
Validation of nomograms for predicting pneumonia in COVID-19
Back to Journals » Journal of Inflammation Research » Volume 17 Authors Xu Y , Li H, Wang X, Li B, Gao A, Zhao Q, Yang L, Qin W, Wang L Received 25 January 2024 Accepted for publication 29 May 2024 Published 7 June 2024 Volume 2024:17 Pages 3671—3683 DOI https://doi.org/10.2147/JIR.S456206 Checked for plagiarism Yes Review by Single anonymous peer review Peer reviewer comments 3 Editor who approved publication: Professor Ning Quan Yiyue Xu,1,* Haoqian Li,1,* Xiaoqing Wang,2 Butuo Li,1...
Pneumonitis with combined immune checkpoint inhibitors and chemoradiotherapy in locally advanced non-small-cell lung cancer: a systematic review and meta-analysis | Future Oncology
This research was supported by National Natural Science Foundation of China (grant no. 82172865), Start-up fund of Shandong Cancer Hospital (grant no. 2020-B14), Clinical Research Special Fund of Wu Jieping Medical Foundation (grant nos. 320.6750.2021-02-51 and 320.6750.2021-17-13).
Clinical implications of germline BCL2L11 deletion polymorphism in pretreated advanced NSCLC patients with osimertinib therapy
Highlights • This is the first study to evaluate the role of BIM status in NSCLC patients undergoing osimertinib treatment. • EGFR T790 M NSCLC patients with a BIM deletion polymorphism (BIM-del) had a poor objective response rate. • Patients with T790 M/BIM-del had a significantly shorter progression-free survival (PFS) and a moderately shorter overall survival (OS). • Multivariate cox analysis indicated that BIM-del was an independent prognostic factor for PFS but not OS.
Local therapy combined with chemotherapy versus chemotherapy for postoperative oligometastic non-small-cell lung cancer
Metrics Downloaded 0 times History Received 13 December 2018 Accepted 21 February 2019 Published online 11 March 2019 Information © 2019 Future Medicine Ltd KeywordsAuthor contributions L Wang and J Yu designed the study; S Shang, Y Su, B Li, M Guo, Z Zhu and X Sun performed the data analyses and drafted the manuscript; L Wang and J Yu revised the paper.
Show More
loading
Actions
Is this you?
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.Get in touch with Butuo
Contact Butuo, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack